To help prevent medical product shortages and ensure access to essential drugs and devices, the Food and Drug Administration should make information on medical product sourcing, manufacturing capacity and quality publicly available for all medical products approved or cleared for sale in the United States, according to a new congressionally mandated report from the National Academies of Sciences, Engineering, and Medicine. Among other actions, the report calls for the Office of the Assistant Secretary for Preparedness and Response to develop ways to better manage the Strategic National Stockpile and convene a stakeholder group to improve medical product allocation and delivery during shortages; health systems to incorporate quality and reliability into their contracting, purchasing and inventory decisions; and countries to negotiate an international treaty that prohibits export bans on critical products.

Related News Articles

Headline
The AHA June 7 submitted comments on a discussion draft of the Drug Shortage Prevention and Mitigation Act, bipartisan legislation proposing to provide…
Blog
The inability of many patients to obtain needed drug therapies due to either high prices or shortages has negatively affected patient outcomes.1 Nearly 30% of…
Headline
ASHP tracked a record 323 active drug shortages during the first quarter of 2024, surpassing the previous record of 320 shortages in 2014.“Some of the most…
Headline
The Department of Health and Human Services April 2 released a white paper proposing policy solutions for Congress and others to prevent drug shortages and…
Headline
In a statement submitted to the House Ways and Means Committee for a hearing Feb. 6 on chronic drug shortages, AHA recommended Congress enact legislation to…
Headline
Reps. Doris Matsui, D-Calif., and Larry Bucshon, R-Ind., Jan. 12 introduced a House version of the Mapping America’s Pharmaceutical Supply Act, legislation…